KPTI earnings analysis
What we found in KPTI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Karyopharm generated $33.432 million of Q2 revenue, led by $30.8 million of U.S. XPOVIO product revenue, but revenue declined from both the prior quarter and prior-year period while diluted EPS was a $2.32 loss. The company reported a $22.5 million operating loss and disclosed substantial doubt about its ability to continue as a going concern, with liquidity expected to last only into September 2026. The maintained $130 million-$150 million full-year revenue outlook is outweighed by the September 10, 2026 debt payment, covenant risk, and the failed endometrial-cancer trial.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined sequentially and year over year
- Q2 revenue was $33.432 million, down from $35 million in Q1 2026 and $38 million in Q2 2025, representing sequential and year-over-year declines of approximately 4% and 12%, respectively.
- XPOVIO remains the core revenue driver
- U.S. XPOVIO product revenue was $30.8 million and royalty revenue was $2.5 million, together representing approximately $33.3 million of the $33.432 million quarterly revenue base.
- Full-year revenue outlook maintained
- Management maintained full-year 2026 total revenue guidance of $130 million-$150 million and U.S. XPOVIO revenue guidance of $115 million-$130 million.
- Lower operating expenses
- Operating expenses declined, although the company still reported a $22.5 million loss from operations for the quarter ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern uncertainty
- The company stated that its $65.1 million of cash, cash equivalents and investments is expected to fund current operating plans only into September 2026. Management concluded there is substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Near-term debt and covenant pressure
- A $15.8 million principal payment is due on September 10, 2026. If paid without new financing or a lender waiver, liquidity is expected to fall below the $10.0 million minimum-liquidity covenant and trigger a term-loan default; approximately $10.1 million of additional interest payments are due on September 30, 2026.
- Endometrial cancer trial failure
- The July 2026 Phase 3 XPORT-EC-042 endometrial-cancer trial did not meet the pre-specified statistical-significance threshold for its primary progression-free-survival endpoint, and the company does not expect to pursue U.S. regulatory approval in that indication.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.32
- Segment
- U.S. XPOVIO net product revenue: $30.8 million
- Segment
- Royalty revenue: $2.5 million
- Segment
- Total revenue: $33.432 million
What they said about what is next.
Management maintained full-year 2026 total revenue guidance of $130 million-$150 million, U.S. XPOVIO net product revenue guidance of $115 million-$130 million, and R&D plus SG&A expense guidance of $230 million-$245 million, excluding certain one-time costs.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Karyopharm Therapeutics reported improved Q1 2026 results, with revenues of $35.1 million and a diluted EPS of -$1.24, exceeding expectations. The company reaffirmed a full-year revenue guidance of $130M to $150M amid…
- 10-K · February 13, 2026
- Karyopharm’s 2025 10‑K highlights commercialization of XPOVIO and active late‑stage clinical programs but discloses a stressed balance sheet. The company reported $146.1 million of total revenue in 2025 (including…
- 10-Q · November 3, 2025
- Karyopharm reported Q3 2025 revenue of $44.044 million, up from $38.783 million in Q3 2024, driven by higher product ($32.032M) and license/other revenue ($12.012M). Gross margin remained high at ~95.2% but operating…
- 10-Q · August 11, 2025
- Karyopharm reported Q2 revenue of $37.929M, down from $42.786M a year ago, while product (XPOVIO) revenue rose to $29.681M (+$1.649M YoY). Gross margin remained very high at ~97.2% and operating loss improved to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KPTI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever